Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 17/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278338 | 0.96 | ABCB1 (0.62) | ABCB1KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL1262957 | 0.84 | HDAC6 (0.64) | ABCB1KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL2278782 | 0.82 | ABCB1 (0.52) | ABCB1KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL1264307 | 0.82 | NPC1 (0.59) | ABCB1KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL1264533 | 0.80 | KMT2A (0.63) | ABCB1KMT2ARXFP1HRH4 | |
| SCHEMBL1028801 | 0.79 | ABCB1 (0.52) | ABCB1KMT2ARXFP1NPC1RAB9A | |
| SCHEMBL29078323 | 0.78 | HDAC6 (0.72) | KMT2ARXFP1NPC1RAB9AHRH4 | |
| SCHEMBL1264296 | 0.76 | HDAC6 (0.70) | — | |
| SCHEMBL1429630 | 0.76 | HRH4 (1.00) | KMT2ANPC1RAB9AHRH4 | |
| SCHEMBL12334808 | 0.75 | HRH4 (0.81) | KMT2ANPC1RAB9AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | claimed |
| EP-2274283-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-01-19 | — | — | EP | claimed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | claimed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2274283-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | HDAC1, HDAC3, HDAC4 | ABCB1 3334/4885KMT2A 60/4885RXFP1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.